Alpha 2.0
Login Register
» Authors » C Chevreau

C Chevreau

Explore the profile of C Chevreau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 119
Citations 2230
Followers 0
Related Specialties
Oncology
Urology
General Surgery
Top 10 Co-Authors
A Le Cesne
A Italiano
N Penel
R Bugat
E Bompas
P Canal
J Y Blay
F Bertucci
I Ray-Coquard
S Piperno-Neumann
Published In
Ann Oncol
Bull Cancer
J Clin Oncol
Prog Urol
Eur J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
Le Cesne A, Chevreau C, Perrin C, Italiano A, Hervieu A, Blay J, et al.
ESMO Open . 2023 Jun; 8(3):101569. PMID: 37285716
Background: REGOBONE multicohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the cohort of patients with relapsed advanced or metastatic chordoma....
2.
Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
Debaudringhien M, Blay J, Bimbai A, Bonvalot S, Italiano A, Rousset-Jablonski C, et al.
ESMO Open . 2022 Sep; 7(5):100578. PMID: 36116422
Background: The role of both hormonal contraception and pregnancy on the outcomes of desmoid-type fibromatosis (DF) is debatable. Materials And Methods: In the present study, we selected female patients of...
3.
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al.
Nat Med . 2022 May; 28(6):1199-1206. PMID: 35618839
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in...
4.
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
Moreau-Bachelard C, Campion L, Toulmonde M, Le Cesne A, Brahmi M, Italiano A, et al.
ESMO Open . 2022 Feb; 7(2):100402. PMID: 35202953
Background: Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic...
5.
Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment
Attal J, Cabarrou B, Valentin T, Nesseler J, Stoeckle E, Ducassou A, et al.
Strahlenther Onkol . 2021 Oct; 197(12):1051-1062. PMID: 34673991
Purpose: Patients with locally advanced grade 2-3 extremity/truncal soft tissue sarcomas (STS) are at high risk of recurrence. The objective of this study was to assess the efficacy and feasibility...
6.
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, et al.
ESMO Open . 2021 Jul; 6(4):100209. PMID: 34325109
Background: Uterine leiomyosarcomas (U-LMSs) and soft tissue leiomyosarcomas (ST-LMSs) are rare tumours with poor prognosis when locally advanced or metastatic, and with moderate chemosensitivity. In 2015 we reported very encouraging...
7.
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
Le Cesne A, Blay J, Cupissol D, Italiano A, Delcambre C, Penel N, et al.
Ann Oncol . 2021 May; 32(8):1034-1044. PMID: 33932507
Background: The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS). Patients...
8.
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
Brahmi M, Lesluyes T, Dufresne A, Toulmonde M, Italiano A, Mir O, et al.
ESMO Open . 2021 Feb; 6(1):100037. PMID: 33524869
Background: While the anti-PDGFRA antibody olaratumab failed to confirm an impact on survival in unselected advanced soft tissue sarcoma (STS) patients, the level of expression and the prognosis of platelet-derived...
9.
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
Dufresne A, Lesluyes T, Menetrier-Caux C, Brahmi M, Darbo E, Toulmonde M, et al.
Oncoimmunology . 2020 Sep; 9(1):1792036. PMID: 32923153
Soft tissue sarcomas are a group of rare and aggressive connective tissue neoplasms for which curative therapeutic opportunities are limited in advanced phase. Clinical trials assessing immunotherapy in these tumors...
10.
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
Pautier P, Penel N, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, et al.
Eur J Cancer . 2019 Dec; 125:31-37. PMID: 31835236
Background: Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib (P) monotherapy. Currently, no combination therapy is better than monotherapy. LMS03 is an...